P

    Puma Biotechnology Inc (PBYI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.11
    +0.05 (+0.55%)

    Market Cap: $467.68M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    80%(32/40)
    Avg Surprise
    +54.27%
    Streak
    10 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.12
    Range$0.12 - $0.12
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.19+58.3%
    60d ago$0.19+58.3%
    30d ago$0.19+58.3%
    7d ago$0.19+58.3%
    Current$0.12
    Revenue Consensus
    $58M
    Range$58M - $58M
    1 analysts
    Dec 31, 2026
    EPS Consensus$0.49
    Range$0.49 - $0.49
    1 analysts
    Revenue Consensus
    $-152500000
    Range$-152500000 - $-152500000
    0 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.49---
    Sep 26EST
    		-$0.12---
    Jun 26
    		$0.16$0.06+166.67%Beat+33.3%
    Mar 26
    		$-0.04N/A+69.23%Beat-166.7%
    Dec 25
    		$0.26$0.19+36.84%Beat-39.5%
    Sep 25
    		$0.21$0.09+133.33%Beat-53.3%
    Jun 25
    		$0.12$0.08+50.00%Beat+340.0%
    Mar 25
    		$0.06$-0.02+400.00%Beat+220.0%
    Dec 24
    		$0.43$0.14+207.14%Beat+65.4%
    Sep 24
    		$0.45$0.38+18.42%Beat+164.7%
    Jun 24
    		$-0.05$-0.10+50.00%Beat-150.0%
    Mar 24
    		$-0.05N/A+66.67%Beat-155.6%
    Dec 23
    		$0.26$0.30-13.33%Miss+316.7%
    Sep 23
    		$0.17$0.14+21.43%Beat+240.0%
    Jun 23
    		$0.10$0.07+42.86%Beat-64.3%
    Mar 23
    		$0.09$-0.01+1000.00%Beat+1000.0%
    Dec 22
    		$-0.12$0.01-1300.00%Miss-220.0%
    Sep 22
    		$0.05$0.03+66.67%Beat+105.1%
    Jun 22
    		$0.28$0.09+211.11%Beat-12.5%
    Mar 22
    		$-0.01N/A+90.91%Beat-101.8%
    Dec 21
    		$0.10$-0.09+211.11%Beat+126.3%
    Sep 21
    		$-0.99$-0.22-350.00%Miss-65.0%
    Jun 21
    		$0.32$-0.14+328.57%Beat-8.6%
    Mar 21
    		$0.55$0.34+61.76%Beat+375.0%
    Dec 20
    		$-0.38$-0.31-22.58%Miss-3900.0%
    Sep 20
    		$-0.60$-0.14-328.57%Miss-400.0%
    Jun 20
    		$0.35$0.14+150.00%Beat+161.4%
    Mar 20
    		$-0.20N/A+70.59%Beat-200.0%
    Dec 19
    		$0.01N/A+103.85%Beat+101.3%
    Sep 19
    		$-0.12N/A+73.33%Beat-175.0%
    Jun 19
    		$-0.57$-0.89+35.96%Beat+3.4%
    Mar 19
    		$0.20$-0.20+200.00%Beat+900.0%
    Dec 18
    		$-0.80$-0.77-3.90%Miss+53.2%
    Sep 18
    		$0.16N/A+135.56%Beat+111.8%
    Jun 18
    		$-0.59$-0.82+28.05%Beat+57.2%
    Mar 18
    		$0.02N/A+106.45%Beat+101.7%
    Dec 17
    		$-1.71$-1.97+13.20%Beat+16.2%
    Sep 17
    		$-1.36$-1.42+4.23%Beat-22.5%
    Jun 17
    		$-1.38$-1.31-5.34%Miss-
    Mar 17
    		$-1.16$-1.20+3.33%Beat-
    Dec 16
    		$-2.04$-1.92-6.25%Miss-
    Sep 16
    		$-1.11$-1.96+43.37%Beat-

    Key Metrics

    Valuation
    P/E Ratio15.44EV/EBITDA8.59x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin11.60%Operating Margin13.40%
    ROE22.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage8.76x
    Current Ratio2.91xQuick Ratio2.64x
    Trading Statistics
    Beta1.22Avg Volume320.82K
    52-Week High$9.5152-Week Low$4.30

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$9.21
    SMA 20$8.88
    SMA 50$8.39
    SMA 200$6.97
    EMA 10$9.10
    EMA 20$8.90
    EMA 50$8.42
    EMA 200$7.06

    MACD

    Line: 0.28Signal: 0.29Hist: -0.02

    ADX

    ADX: 24.4+DI: 21.8-DI: 19.8

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down20.0
    PSAR$8.21

    Bollinger Bands

    Upper Band$9.78
    Lower Band$7.98
    %B Position2027%(Upper)
    Band Width0.63

    RSI (14-Day)

    Neutral
    57.6

    Momentum Oscillators

    Stoch %K63.1
    Stoch %D70.1
    Williams %R-40.8
    ROC (10d)3.3%
    Momentum0.29
    CCI (20d)33.1
    MFI (14d)43.9

    Volatility Measures

    ATR (14d)$0.38(4.1%)
    StdDev (20d)0.45
    Hist Vol47.1%(High)

    Volume Flow

    VWAP$9.03
    OBV27.5M
    AD Line16.8M
    CMF (20d)0.138

    Volume Metrics

    Avg Vol (20d)319.9K
    Vol Ratio0.8x
    VWMA (20d)$8.86

    Pivot Points

    R3$9.45
    R2$9.35
    R1$9.21
    Pivot Point$9.11
    S1$8.97
    S2$8.87
    S3$8.73

    Advanced Oscillators

    TSI21.30
    Ultimate Osc56.0
    KST126.94

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$56.50M$44.81M$75.45M$54.48M$52.44M$46.01M$59.08M$80.54M$47.08M$43.77M$72.18M$56.12M
    Cost of Revenue$12.47M$10.42M$23.13M$12.17M$12.30M$10.56M$13.92M$29.10M$10.66M$10.73M$24.32M$13.28M
    Gross Profit$44.03M$34.39M$52.33M$42.30M$40.13M$35.45M$45.16M$51.45M$36.42M$33.04M$47.85M$42.83M
    Operating Expenses$36.44M$38.22M$35.22M$32.73M$33.50M$31.47M$31.79M$29.37M$38.60M$35.34M$33.06M$34.25M
    R&D$18.89M$19.80M$16.84M$15.91M$15.45M$13.86M$15.17M$12.55M$13.63M$13.59M$12.87M$11.45M
    SG&A$17.55M$18.42M$18.38M$16.82M$18.05M$17.60M$16.62M$16.82M$24.97M$21.75M$20.18M$22.80M
    Operating Income$7.58M$-3,828,000$17.11M$9.57M$6.64M$3.98M$13.37M$22.08M$-2,179,000$-2,299,000$14.80M$8.59M
    Interest Income$831,000$1.00M$977,000$1.04M$956,000$1.10M$1.23M$1.28M$1.24M$972,000$719,000$689,000
    Interest Expense$180,000$731,000$1.12M$1.49M$1.84M$2.18M$2.62M$3.10M$3.37M$3.36M$3.35M$3.34M
    Income Before Tax$8.24M$-3,427,000$17.11M$9.24M$6.17M$3.27M$12.24M$20.61M$-4,151,000$-4,595,000$12.80M$6.01M
    Income Tax Expense$56,000$326,000$3.67M$399,000$310,000$293,000$-7,067,000$291,000$378,000$220,000$536,000$213,000
    Net Income$8.19M$-3,753,000$13.44M$8.84M$5.86M$2.97M$19.30M$20.32M$-4,529,000$-4,815,000$12.27M$5.80M
    EBITDA$10.11M$-1,114,000$19.91M$12.41M$9.81M$7.14M$16.47M$25.30M$885,000$689,000$18.33M$11.54M
    EBIT$7.59M$-3,698,000$17.25M$9.69M$7.05M$4.34M$13.63M$22.43M$-2,023,000$-2,208,000$15.44M$8.66M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PBYI

    News

    PBYI | PUMA BIOTECHNOLOGY INC Financials - Revenue Breakdown

    This article provides a financial overview of Puma Biotechnology Inc. (PBYI), focusing on its revenue breakdown, Congressional trading activity, and institutional ownership. It highlights past stock trades by U.S. Congress members and notes the absence of specific revenue segmentation data. The article also includes details about the company's business, such as its focus on cancer care products like NERLYNX.

    Quiver Quantitative•8/23/26•
    Neutral

    Puma Biotechnology (NASDAQ:PBYI) Upgraded at Wall Street Zen

    Wall Street Zen upgraded Puma Biotechnology (NASDAQ:PBYI) from a "buy" to a "strong-buy" rating, despite the broader analyst consensus remaining "hold" with a $6.00 price target. The company reported strong quarterly earnings, beating EPS and revenue estimates, though insiders have sold a significant number of shares recently. Institutional ownership remains high at 61.29%.

    MarketBeat•8/15/26•
    Somewhat-Bullish

    Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript

    Puma Biotechnology reported strong Q2 2026 financial results, with total revenue reaching $56.5 million, primarily driven by increased demand for NERLYNX. The company is now debt-free after repaying its Athyrium loan and has raised its full-year guidance for both product revenue and net income. Puma is also progressing with its clinical trials for alisertib in small cell lung cancer and HER2-negative, hormone receptor-positive breast cancer, and is actively seeking business development opportunities to diversify its portfolio.

    The Globe and Mail•8/14/26•
    Bullish

    Puma Biotechnology, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:PBYI) 2026-08-10

    Puma Biotechnology, Inc. (PBYI) released its Q2 2026 earnings call presentation. The company reported an EPS of $0.20, beating estimates by $0.13, and revenue of $56.50M, exceeding expectations by $3.50M with a 7.82% year-over-year increase. This presentation was published in conjunction with their earnings call on August 10, 2026.

    Seeking Alpha•8/10/26•
    Bullish

    Puma Biotechnology (PBYI) Stock Jumps On Profit Strength As Earnings Outlook Fades

    Puma Biotechnology (PBYI) saw its stock jump 9.7% after reporting strong Q2 2026 earnings, driven by NERLYNX revenue and increased net income. While current profitability and raised full-year guidance are positive, analysts project weaker earnings in the future, creating a tension between present strength and a softer outlook. Investors are weighing the company's ability to sustain NERLYNX growth and fund new drug development against concerns about single-drug reliance and increasing R&D costs.

    Sahm•8/8/26•
    Neutral

    Frequently Asked Questions About PBYI

    Does PBYI pay dividends?
    Puma Biotechnology Inc (PBYI) does not currently pay a regular dividend.
    What is PBYI's P/E ratio?
    Puma Biotechnology Inc has a price-to-earnings (P/E) ratio of 15.44.
    What is PBYI's market cap?
    Puma Biotechnology Inc (PBYI) has a market capitalization of $467.68M with a current stock price of $9.11.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In